Skip to main content
PYC THERAPEUTICS LIMITED logo

PYC THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PYC ISIN · AU000000PYC7 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,297 across all filing types
Latest filing 2017-10-30 Governance Information
Country AU Australia
Listing ASX PYC

About PYC THERAPEUTICS LIMITED

https://pyctx.com/

PYC Therapeutics Limited is a clinical-stage company focused on developing precision medicines for patients with rare genetic diseases. The company utilizes a proprietary drug delivery platform that combines naturally derived cell-penetrating peptides with antisense oligonucleotides to create RNA-based therapeutics. This platform is designed to overcome the challenges of delivering large therapeutic molecules into target cells, particularly within the eye and central nervous system. PYC's primary pipeline includes VP-001, a candidate for Retinitis Pigmentosa type 11, and PYC-001, targeting Autosomal Dominant Optic Atrophy. Additionally, the company is advancing programs for Polycystic Kidney Disease. By leveraging its delivery technology, PYC aims to address the underlying genetic causes of diseases that currently lack effective treatment options.

Recent filings

Filing Released Lang Actions
Appendix 4G 10 pages 125.9KB
Governance Information Classification · 95% confidence The document is titled 'Appendix 4G Key to Disclosures Corporate Governance Council Principles and Recommendations' and references ASX Listing Rules 4.7.3 and 4.10.3. It is a corporate governance statement related to the financial year ended 30 June 2017 for Phylogica Limited. The document discusses compliance with corporate governance principles and recommendations, including board structure, roles, responsibilities, and disclosures. It is not a full annual report but a governance disclosure document that accompanies the annual report as required by ASX rules. The document is lengthy (15,000 characters) and contains detailed governance disclosures rather than financial statements or audit information. This fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2017-10-30 English
Appendix 3X and Appendix 3Z 6 pages 192.0KB
Director's Dealing Classification · 100% confidence The document contains Appendix 3X and 3Z forms related to director's interest notices, specifically the appointment of Mr. Sahm Nasseri and retirement of Mr. Rick Kendall. These forms are regulatory filings required by the ASX listing rules and Corporations Act, reporting personal shareholdings and interests of directors. The content is focused on director share interests and changes in directorship, not on financial results, management reports, or other types of filings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions or interests by company directors and executives. The document length and content confirm it is not a brief announcement or a report publication notice but a substantive regulatory filing of director interests.
2017-10-25 English
Appendix 3B and Appendix 3Y 15 pages 301.7KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement titled 'Appendix 3B and 3Y' related to the exercise of unlisted options and the issuance of new ordinary shares by Phylogica Limited. It includes detailed information about the new issue of securities, compliance with ASX listing rules, and changes in directors' interests. The document is regulatory in nature, focusing on capital changes and director dealings but does not contain financial statements or management discussion. It is primarily an announcement of a new share issue and director interest change, with the main form being Appendix 3B (New Issue Announcement) and Appendix 3Y (Change in Directors Interest Notice). According to the filing definitions, Appendix 3B corresponds to Share Issue/Capital Change (SHA), and Appendix 3Y corresponds to Director's Dealing (DIRS). Since the document includes both but is primarily focused on the new issue announcement (Appendix 3B) and the exercise of options leading to new shares, the most appropriate classification is Share Issue/Capital Change (SHA). Confidence is high due to the explicit mention of Appendix 3B and detailed issuance information.
2017-10-25 English
Notice of Annual General Meeting/Proxy Form 34 pages 462.7KB
AGM Information Classification · 95% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes detailed agenda items typical for an AGM notice, such as financial statements consideration, adoption of remuneration report, election and re-election of directors, ratification of share placement, approval of termination benefits, issue of related party options, adoption of employee share option plan, and renewal of takeover provisions. It specifies the meeting date, time, and place, and provides voting instructions. The content is consistent with materials distributed to shareholders prior to an AGM to inform them of the business to be conducted and to solicit votes. It is not the actual Annual Report or financial statements themselves, but a notice of the meeting where these will be discussed and voted upon. Therefore, the document fits the category of AGM Information (AGM-R). The document length (15,000 characters) and detailed agenda support this classification with high confidence.
2017-10-25 English
Establishment and Appointments to Scientific Advisory Board 3 pages 441.3KB
Board/Management Information Classification · 95% confidence The document is a company announcement dated 25th October 2017 from Phylogica Limited regarding the establishment and appointments to a Scientific Advisory Board (SAB). It details the names, roles, and biographies of the appointed members, as well as the purpose and expected activities of the SAB. There is no financial data, regulatory filing references, voting results, or report publication information. The content focuses on management and board-level appointments and organizational structure changes related to the advisory board. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 7982 characters, which is sufficient for a detailed announcement but does not contain financial statements or report data to classify as an Annual Report or Interim Report. Hence, the classification is MANG with high confidence.
2017-10-24 English
Quarterly Update and Appendix 4C 9 pages 144.4KB
Interim / Quarterly Report Classification · 95% confidence The document is an operational update for the September quarter, including progress highlights, forward-looking statements, and details about a conference call to discuss the quarter's activities. It also contains an Appendix 4C, which is a quarterly report for entities subject to Listing Rule 4.7B, including detailed cash flow statements and financial data for the quarter ended 30 September 2017. The presence of substantive financial data and analysis for a quarter shorter than a full fiscal year, combined with operational updates and forward-looking commentary, indicates this is a comprehensive interim/quarterly report. It is not merely an announcement or invitation, nor is it a full annual report or earnings release. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q3 2017
2017-10-24 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.